1 证券代码：600812 股票简称：华北制药 编号：临 2020-030 华北制药股份有限公司 关于举行 2020 年投资者网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 召开时间：2020 年 6 月 12 日 下午 15:50-17:00 召开方式：网络平台在线交流互动 一、活动会类型 为便于广大投资者更深入全面地了解公司情况、发展战略、经营状况、 融资计划、股权激励、可持续发展等投资者所关心的问题，公司将举行 2020 年投资者网上集体接待日活动。本次年度集体接待日活动将在深圳市全景 网络有限公司提供的网上平台采取网络远程互动的方式举行，投资者可以 登录"河北辖区上市公司投资者关系互动平台"（http://rs.p5w.net）参 与交流。 月 12 日 下午 15:50-17:00 召开方式：网络平台在线交流互动 二、召开的时间和方式 召开时间：2020年6 三、参加人员 公司董事会秘书、副总经理常志山先生； 公司总会计师、财务负责人王立鑫先生。 四、投资者参加方式 投资者可于 202 ...

Financial Performance - Operating revenue decreased by 17.10% to CNY 2,210,078,708.77 year-on-year[11] - Net profit attributable to shareholders increased by 104.49% to CNY 62,972,494.19 compared to the same period last year[11] - The company reported a net profit excluding non-recurring gains and losses of CNY -18,200,832.76, a decrease of 188.87% year-on-year[11] - The company's total revenue for Q1 2020 was CNY 2,210,078,708.77, a decrease from CNY 2,665,889,824.51 in Q1 2019, representing a decline of approximately 17%[39] - The net profit for Q1 2020 was CNY 57,587,111.07, compared to CNY 29,543,447.15 in Q1 2019, showing an increase of approximately 95%[43] - The company achieved a total comprehensive income of CNY 58,568,730.84 in Q1 2020, up from CNY 28,125,424.53 in Q1 2019, indicating a growth of approximately 108%[45] - The total profit for Q1 2020 was CNY 40,093,126.16, a significant increase from CNY 18,708,256.94 in Q1 2019, representing a growth of approximately 114.5%[48] Cash Flow and Liquidity - Net cash flow from operating activities decreased by 68.14% to CNY 74,673,262.59 compared to the previous year[11] - The net cash flow from operating activities for Q1 2020 was CNY 74,673,262.59, down from CNY 234,407,319.07 in Q1 2019, indicating a decrease of about 68.2%[52] - Cash flow from financing activities generated a net inflow of CNY 2,378,050,764.00 in Q1 2020, a substantial increase from CNY 326,141,366.30 in Q1 2019[54] - The ending balance of cash and cash equivalents was CNY 3,346,245,069.37 at the end of Q1 2020, up from CNY 1,394,489,426.96 at the end of Q1 2019, marking an increase of approximately 140.5%[54] - The company reported a cash increase of CNY 1,553,843,449.19 during the period, compared to CNY 199,263,039.91 previously[57] Assets and Liabilities - Total assets increased by 13.11% to CNY 20,971,440,232.84 compared to the end of the previous year[11] - Cash and cash equivalents increased to ¥3,363,792,236.74, a 175.07% increase from ¥1,222,873,259.17 at the end of the previous year, primarily due to increased financing[20] - Long-term borrowings increased by 40.10% to ¥2,306,287,658.00 from ¥1,646,200,000.00, primarily due to additional working capital loans[20] - The total liabilities increased significantly, with cash received from borrowings rising by 118.44% to ¥5,102,854,346.58 from ¥2,336,000,000.00[22] - Current liabilities totaled ¥11,889,107,617.13, an increase from ¥10,080,408,979.40, indicating a growth of approximately 17.9%[32] - The total liabilities were CNY 12,917,137,400.78, showing a stable leverage position[61] Shareholder Information - The total number of shareholders at the end of the reporting period was 91,313[14] - The top three shareholders held a combined 52.66% of the shares, with the largest shareholder owning 21.60%[14] - The total equity attributable to shareholders increased to ¥5,624,143,717.41 from ¥5,560,028,966.47, representing a growth of approximately 1.2%[32] Research and Development - Research and development expenses decreased by 32.69% to ¥16,463,236.68 from ¥24,459,298.91 compared to the same period last year[20] - Research and development expenses for Q1 2020 were CNY 16,463,236.68, down from CNY 24,459,298.91 in Q1 2019, a decrease of approximately 33%[43] Other Financial Metrics - Basic earnings per share rose by 105.26% to CNY 0.039 per share compared to the same period last year[11] - The weighted average return on equity increased by 0.57 percentage points to 1.13%[11] - The company received government subsidies amounting to CNY 82,356,033.68 during the reporting period[13] - The company issued a short-term financing bond of ¥500,000,000.00 during the reporting period[22] - The company reported a decrease in tax payable by 69.67% to ¥38,335,202.89 from ¥126,403,704.91 due to tax payments made during the period[20]

Financial Performance - The company's operating revenue for 2019 was RMB 10,880,767,824.24, representing an increase of 18.09% compared to RMB 9,213,775,284.29 in 2018[25]. - The net profit attributable to shareholders of the listed company was RMB 153,445,292.10, a slight increase of 1.86% from RMB 150,646,419.84 in the previous year[25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses surged by 413.86% to RMB 115,571,913.13 from RMB 22,490,775.36 in 2018[25]. - The net cash flow from operating activities was RMB 732,966,510.66, down by 5.34% from RMB 774,325,700.79 in 2018[25]. - As of the end of 2019, the net assets attributable to shareholders of the listed company were RMB 5,560,028,966.47, an increase of 2.16% from RMB 5,442,464,535.38 at the end of 2018[25]. - The total assets of the company reached RMB 18,541,191,276.57, reflecting a growth of 3.48% compared to RMB 17,916,817,368.08 at the end of 2018[25]. - Basic earnings per share for 2019 was CNY 0.094, a 2.17% increase compared to CNY 0.092 in 2018[26]. - The net profit attributable to shareholders for Q4 2019 was CNY 61,915,844.33, with a total annual revenue of CNY 10,880,167,824.24[29]. - The company achieved a 407.14% increase in basic earnings per share after excluding non-recurring gains and losses, from CNY 0.014 in 2018 to CNY 0.071 in 2019[26]. - The weighted average return on equity increased by 1.68 percentage points to 2.10% after excluding non-recurring gains and losses[26]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of RMB 0.30 per 10 shares, totaling RMB 48,924,141.87, which accounts for 31.88% of the net profit attributable to shareholders for the year[7]. - The company will not conduct capital reserve transfers to increase share capital this period[7]. Industry Overview - The pharmaceutical manufacturing industry saw an 8% year-on-year increase in revenue, with a total of CNY 26,147.4 billion in 2019[38]. - The antibiotic market is experiencing a slowdown in growth, but demand for anti-infection drugs is expected to maintain stable growth in the coming years[90]. - The biopharmaceutical industry has seen sales growth rates of 15% to 33% globally over the past decade, with China entering a phase of large-scale industrialization[91]. - The cardiovascular drug market is projected to grow steadily due to the aging population and increasing incidence of cardiovascular diseases[92]. - The immunosuppressant market is expanding rapidly, driven by the rising number of organ transplant surgeries in China[93]. - The health industry in China is still in its early stages, with significant growth potential, projected to reach a market size of 8 trillion yuan by 2020[96]. - The 2019 medical insurance reform emphasizes structural adjustments and cost control, impacting drug pricing and procurement processes[97]. - The government is promoting centralized drug procurement and quality improvement, which will enhance market competition and efficiency[98]. - The healthcare sector is undergoing reforms to optimize medical service pricing and improve the management of drug usage in medical institutions[99]. Research and Development - Total R&D investment reached 366.46 million yuan, representing 3.37% of operating revenue[77]. - The company has 536 R&D personnel, making up 4.88% of the total workforce[77]. - The company has established a complete R&D system, including a national key laboratory for antibody drug development[131]. - The company is focusing on key R&D projects and has made progress in the consistency evaluation of generic drugs, despite the high risks and long cycles associated with drug development[138]. - The company is actively increasing R&D efforts in biopharmaceuticals, cardiovascular, oncology, metabolism, and immune regulation fields to support sustainable development[148]. - The company is committed to improving the authenticity, scientific nature, and standardization of the drug development process[104]. - The company is preparing for clinical trials for several products, including Daptomycin and Obeticholic Acid, which have received FDA approval for specific indications[152]. Product and Market Strategy - The company focuses on high-value and high-growth projects, particularly in biopharmaceuticals and oncology treatments[33]. - The company aims to transition from a focus on generic drugs to innovative drugs, capturing market share with new products[104]. - The company is committed to sustainable development through green manufacturing and resource optimization[182]. - The company aims to enhance its R&D capabilities and become a leading pharmaceutical R&D center in China[182]. - The company is actively pursuing structural adjustments and enhancing its marketing innovation strategies[62]. - The company is committed to strengthening its market position by expanding strategic partnerships and enhancing collaboration with key distributors[159]. Financial Management and Investments - The company reported a net profit of 148 million yuan, with a significant difference of 585 million yuan from operating cash flow due to non-cash expenses[81]. - The total liabilities increased, with long-term borrowings rising by 108.49% to 1.65 billion yuan, optimizing the financing structure[85]. - Short-term borrowings increased by 36.56% to 6.28 billion yuan, reflecting a rise in bank loans[83]. - The company has ongoing projects with significant investments, including a new park construction project with a total investment of approximately ¥578.44 million[170]. - The company aims to integrate its pharmaceutical business with Huayao Group to achieve a unified platform for pharmaceutical operations[197]. Sales and Distribution - The company has established a nationwide sales network covering most provinces and municipalities, utilizing a "distribution +招商 + academic promotion" sales model[153]. - The company is transitioning its sales strategy from primarily招商 to a focus on academic, clinical, and terminal promotion to enhance market coverage and reduce distribution costs[159]. - The company is preparing for the clinical trial of its recombinant human anti-TNF-α monoclonal antibody injection, targeting rheumatoid arthritis and ankylosing spondylitis[152]. Risk Management - The company reported no significant risks that could materially affect its operations during the reporting period[9]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[9]. - The company will actively respond to industry policy adjustments and market changes to reduce operational risks[188].

2019 年第三季度报告 公司代码：600812 公司简称：华北制药 华北制药股份有限公司 2019 年第三季度报告 1 / 29 2019 年第三季度报告 一、 重要提示 二、 公司基本情况. 11[ 重要事项 四、 附录 目录 2 / 29 2019 年第三季度报告 单位：元 币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司董事长杨国占、总经理周晓冰、总会计师、财务负责人王立鑫及财务部部长李建军保证 季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | |-----------------------------------------------|------------------------------|------------------------------------|----- ...

Financial Performance - The company's operating revenue for the first half of 2019 was ¥5,332,197,956.13, representing a 13.00% increase compared to ¥4,718,839,354.95 in the same period last year[23]. - The net profit attributable to shareholders of the listed company was ¥79,422,649.12, an increase of 28.54% from ¥61,788,762.99 in the previous year[23]. - The net profit after deducting non-recurring gains and losses was ¥54,221,395.57, which is a 5.94% increase from ¥51,182,326.25 in the same period last year[23]. - The net cash flow from operating activities was ¥437,142,389.09, showing a decrease of 26.44% compared to ¥594,298,204.99 in the previous year[23]. - The total assets at the end of the reporting period were ¥18,308,557,262.42, reflecting a 2.19% increase from ¥17,916,817,368.08 at the end of the previous year[23]. - The net assets attributable to shareholders of the listed company were ¥5,473,735,849.51, a slight increase of 0.57% from ¥5,442,464,535.38 at the end of the previous year[23]. - The basic earnings per share for the first half of 2019 were ¥0.049, up 28.95% from ¥0.038 in the same period last year[24]. - The diluted earnings per share were also ¥0.049, reflecting the same percentage increase of 28.95% compared to the previous year[24]. - The weighted average return on net assets increased to 1.45%, up by 0.29 percentage points from 1.16% in the previous year[24]. Revenue and Sales - The company generated a profit of RMB 175.49 billion in the first half of 2019, representing a year-on-year growth of 10.3%[39]. - The pharmaceutical manufacturing industry achieved a revenue of RMB 13,223.9 billion in the first half of 2019, with a year-on-year increase of 8.9%[39]. - The chemical pharmaceutical sector's revenue reached RMB 6,551.3 billion, growing by 10.8% year-on-year, with profits of RMB 865.9 billion, up 12.1%[39]. - The company achieved a revenue of 5.432 billion CNY in biopharmaceuticals for the first half of the year, representing a year-on-year growth of 23.56%[47]. - Key products, including injectable amoxicillin sodium clavulanate, generated sales revenue of 1.872 billion CNY, a year-on-year increase of 21.7%[57]. - The total revenue for the first half of the year reached 5.332 billion CNY, with a year-on-year growth of 13%[57]. - The company reported a total profit of 109.6 million CNY, reflecting a year-on-year increase of 33.93%[57]. - Export sales revenue amounted to 839 million CNY in the first half of the year[47]. Research and Development - The company holds 14 authorized invention patents and has applied for 13 additional patents in the first half of the year[58]. - Research and development expenses rose by 14.09% to CNY 1.04 billion, attributed to significant R&D projects and drug consistency evaluation[1]. - The company focuses on high-value and high-growth projects, particularly in biopharmaceuticals and oncology drugs[31]. Compliance and Quality Control - The company emphasizes strict compliance with GMP standards in its production processes to ensure product quality[33]. - The company has implemented a self-monitoring plan and conducts regular monitoring activities to ensure compliance with environmental standards[134]. - The company has established emergency response plans for sudden environmental incidents, with a registration number of 130182-2018-024-M[142]. Environmental Management - The company operates 13 key pollutant discharge units, including North China Pharmaceutical Huasheng Co., Ltd., with specific environmental compliance measures in place[122]. - The actual discharge concentration of Chemical Oxygen Demand (COD) was 221 mg/L, below the limit of 300 mg/L, with a total discharge of 146.601 tons in the first half of 2019[122]. - The company has a wastewater treatment capacity of 7000 tons per day, with normal operational status[125]. - The company has implemented various pollution control facilities, including a fermentation tail gas treatment facility with a capacity of 55,000 m³/h, operational since June 2016[125]. - The company has completed several environmental impact assessments for projects, including the β-lactam semi-synthetic antibiotic transformation project, which passed inspection on November 6, 2000[134]. Community Engagement and Social Responsibility - The company has implemented a poverty alleviation plan with a focus on increasing income for impoverished households, aiming for an average annual income increase of 500-1000 RMB per household by 2020[113]. - The company has actively engaged in community outreach, reaching over 300 households to enhance satisfaction and sense of gain among assisted households[116]. - The company has achieved a collective income increase for the village of no less than 20,000 RMB in 2018[113]. Risks and Strategic Focus - The company faces risks from complex pharmaceutical operating environments and increasing costs in R&D, environmental protection, and funding[81]. - The company plans to adapt to industry policy changes and enhance its product structure and marketing innovation[81]. - The company aims to enhance its market position through strategic partnerships and potential mergers and acquisitions in the pharmaceutical industry[90]. Related Party Transactions - The company expects a total of related party transactions for 2019 to reach CNY 1,018.85 million, with actual transactions amounting to CNY 364.78 million as of June 30, 2019[102]. - Financial-related transactions are projected at CNY 905.65 million, with CNY 312.83 million realized by June 30, 2019, including CNY 200 million in bill business and CNY 74 million in deposits[102]. Legal and Compliance Status - The company reported no major litigation or arbitration matters during the reporting period[98]. - The company maintains a strong integrity status, with no significant debts or court judgments unfulfilled by the company or its major shareholders[99].

Financial Performance - The company's operating revenue for the first half of 2019 was CNY 5,332,197,956.13, representing a 13.00% increase compared to CNY 4,718,839,354.95 in the same period last year[26] - The net profit attributable to shareholders of the listed company was CNY 79,422,649.12, an increase of 28.54% from CNY 61,788,762.99 in the previous year[26] - The net profit after deducting non-recurring gains and losses was CNY 54,221,395.57, which is a 5.94% increase from CNY 51,182,326.25 in the same period last year[26] - The net cash flow from operating activities was CNY 437,142,389.09, showing a decrease of 26.44% compared to CNY 594,298,204.99 in the previous year[26] - The total assets at the end of the reporting period were CNY 18,308,557,262.42, reflecting a 2.19% increase from CNY 17,916,817,368.08 at the end of the previous year[26] - The net assets attributable to shareholders of the listed company were CNY 5,473,735,849.51, which is a 0.57% increase from CNY 5,442,464,535.38 at the end of the previous year[26] - The basic earnings per share for the first half of 2019 were CNY 0.049, up 28.95% from CNY 0.038 in the same period last year[27] - The diluted earnings per share were also CNY 0.049, reflecting the same percentage increase of 28.95% compared to the previous year[27] - The weighted average return on net assets increased to 1.45%, up by 0.29 percentage points from 1.16% in the previous year[27] Industry Overview - The pharmaceutical manufacturing industry achieved a revenue of RMB 13,223.9 billion in the first half of 2019, with a year-on-year growth of 8.9%[42] - The chemical pharmaceutical sector's revenue reached RMB 6,551.3 billion, reflecting a year-on-year increase of 10.8%[42] - The company is one of the largest chemical pharmaceutical enterprises in China, with a strong market position established since its founding in 1953[46] - The pharmaceutical industry in China is characterized by high investment and significant risks associated with new drug development, which typically takes 10-15 years[45] Product Development and Innovation - The company has developed over 700 product specifications, focusing on high-value and high-growth projects in biopharmaceuticals and oncology treatments[34] - The company achieved a revenue of 5.432 billion CNY in biopharmaceuticals for the first half of the year, representing a year-on-year growth of 23.56%[50] - Key products, including injectable amoxicillin sodium clavulanate, generated sales revenue of 1.872 billion CNY, a year-on-year increase of 21.7%, with 13 formulation products exceeding 100 million CNY in revenue[60] - The company is actively advancing the clinical trials of its new drug, a recombinant rabies virus antibody, which is currently in Phase III trials[61] - The company is focusing on the development of new treatment areas, including cardiovascular, anti-tumor, kidney disease, and diabetes products in its new park project[57] Operational Efficiency - The company’s logistics operations leverage its supply chain advantages to provide services and generate revenue[38] - The company’s production strictly adheres to GMP standards, ensuring product quality and safety throughout the manufacturing process[36] - The company has established a comprehensive product chain from raw materials to formulations, particularly excelling in antibiotics[34] Financial Management and Investments - The total investment in new projects reached approximately CNY 578.44 million, with a significant portion funded through self-raised capital and loans[76] - The company reported a significant increase in other income, which rose by ¥20,675,400, mainly due to increased government subsidies[66] - The company’s net profit increased by ¥41,417,300 due to non-operating income adjustments[66] Risks and Challenges - The company reported no significant risks that could materially affect its operations during the reporting period[10] - The company faces risks due to a complex pharmaceutical operating environment, including regulatory changes and rising operational costs[80] Community Engagement and Social Responsibility - The company has implemented a poverty alleviation plan with a goal to ensure that the per capita income of policy beneficiaries exceeds the national poverty standard by 2020[114] - By the end of 2018, the poverty alleviation project ensured that each household benefited by no less than 3,000 RMB, with collective income for villages increasing by no less than 20,000 RMB[114] - The company has initiated various agricultural projects, including a 150-head cattle breeding project and a 100-acre alfalfa planting project, to enhance local income[117] - The company has actively engaged in community outreach, reaching over 300 households to enhance satisfaction and perceived benefits from poverty alleviation efforts[117] Environmental Compliance and Sustainability - The company operates 13 key pollutant discharge units, including Huabei Pharmaceutical Huasheng Co., Ltd., with a focus on environmental compliance[123] - The actual discharge concentration for Chemical Oxygen Demand (COD) was 13.61 mg/L, significantly below the limit of 300 mg/L, with a total discharge of 4.855 tons in the first half of 2019[129] - The company has implemented various pollution control facilities, including a fermentation tail gas treatment facility with a capacity of 55,000 m³/h, which is also operating normally[124] - The company is committed to continuous improvement in environmental protection and compliance with relevant standards[124] - The company has established an emergency response plan for environmental incidents, registered under number 130182-2018-024-M[147] Related Party Transactions - The company expects a total of related party transactions for 2019 to be CNY 1,018.85 million, with CNY 364.78 million actually occurring by June 30, 2019[101] - For production-related transactions, the expected amount is CNY 113.20 million, with CNY 51.95 million realized by June 30, 2019[101] - Financial-related transactions are projected at CNY 905.65 million, with CNY 312.83 million completed, including CNY 200 million in bill business and CNY 74 million in deposits[101] Corporate Governance - The company reported no major litigation or arbitration matters during the reporting period[98] - The company maintains a good integrity status, with no significant debts or court judgments unfulfilled[98] - The company has committed to not misusing company funds or requiring the company to cover costs for wages, benefits, or other expenses[95] - The company has ensured that related party transactions are conducted at market prices to maintain fairness[95]

证券代码：600812 股票简称：华北制药 编号：临 2019-019 华北制药股份有限公司 关于参加"河北辖区上市公司 2019 年度投资者 网上集体接待日暨全国投资者保护宣传日活动"的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 召开时间：2019 年 5 月 15 日 下午 15:00-17:00 召开方式：网络平台在线交流互动 一、活动会类型 为进一步做好投资者关系管理，加强与广大投资者的交流与沟通，提 高公司信息披露透明度，更好地保护投资者合法权益，公司将参加由中国 证监会河北监管局举办的"河北辖区上市公司 2019 年度投资者网上集体接 待日暨全国投资者保护宣传日活动"。公司与广大投资者就 2018 年年报、 公司治理、发展战略、经营状况等投资者所关心的问题，通过深圳全景网 络有限公司互动平台（http://rs.p5w.net），以在线交流形式进行沟通与 交流。 二、召开的时间和方式 1、召开时间：2019 年 5 月 15 日 下午 15:00-17:00 2、召开方式：网络平台在线交流互动 特此 ...

Financial Performance - Operating revenue for the first quarter reached CNY 2,665,889,824.51, an increase of 8.26% year-on-year[12] - Net profit attributable to shareholders was CNY 30,794,259.63, reflecting a growth of 16.46% compared to the same period last year[12] - Basic earnings per share rose by 18.75% to CNY 0.019 from CNY 0.016 in the previous year[12] - Total operating revenue for Q1 2019 was ¥2,665,889,824.51, an increase of 8.25% compared to ¥2,462,469,223.66 in Q1 2018[48] - Net profit for Q1 2019 reached ¥29,543,447.15, representing a 19.5% increase from ¥24,733,984.98 in Q1 2018[50] - The total profit for Q1 2019 was ¥42,409,286.72, an increase of 19.4% from ¥35,534,686.13 in Q1 2018[48] - Total comprehensive income for the first quarter of 2019 was CNY 18,696,592.90, compared to CNY 13,078,760.77 in the same period of 2018, representing an increase of approximately 42.5%[55] Assets and Liabilities - Total assets increased by 2.13% to CNY 18,298,790,264.60 compared to the end of the previous year[12] - The company's prepayments increased by 38.11% to RMB 195,613,301.53 from RMB 141,635,501.35 at the end of the previous year, attributed to unpaid equipment payments[23] - Total liabilities increased to ¥12,758,601,318.28 from ¥12,404,783,693.51, representing a growth of approximately 2.85%[34] - Owner's equity rose to ¥5,540,188,946.32, up from ¥5,512,033,674.57, indicating an increase of about 0.51%[34] - Total current liabilities increased to ¥8,977,424,890.36 from ¥8,822,159,503.67, reflecting an increase of about 1.76%[42] - The company's total liabilities reached ¥12,404,783,693.51, with current liabilities accounting for ¥10,707,619,487.28[75] Cash Flow - Net cash flow from operating activities decreased by 15.48% to CNY 234,407,319.07 compared to the same period last year[12] - Cash inflow from operating activities for Q1 2019 was CNY 2,136,015,376.62, up from CNY 2,042,825,274.88 in Q1 2018, indicating a growth of about 4.6%[60] - Cash outflow from investing activities totaled CNY 158,386,115.87 in Q1 2019, compared to CNY 108,051,845.98 in Q1 2018, reflecting an increase of about 46.6%[61] - Cash inflow from financing activities in Q1 2019 was CNY 2,702,600,000.00, compared to CNY 2,285,338,946.76 in Q1 2018, an increase of about 18.3%[61] Shareholder Information - The total number of shareholders reached 84,736 by the end of the reporting period[19] - The top three shareholders held a combined 52.66% of the total shares, with the largest shareholder owning 21.60%[19] Expenses - Sales expenses rose by 35.73% to RMB 790,082,765.96, reflecting adjustments in marketing strategies and increased terminal sales efforts[23] - Research and development expenses rose to ¥23,266,259.60 in Q1 2019, up from ¥19,669,777.71 in Q1 2018, marking a 18.06% increase[48] Other Income and Gains - Non-recurring gains and losses amounted to CNY 10,313,484.07 for the quarter[15] - The company reported a significant increase in other income, which rose by 98.02% to RMB 13,003,217.86 due to higher government subsidies compared to the previous year[23] - Other income for Q1 2019 was ¥13,003,217.86, up from ¥6,566,625.94 in Q1 2018, reflecting a growth of 98.24%[48]

2019 年第一季度报告 公司代码：600812 公司简称：华北制药 华北制药股份有限公司 2019 年第一季度报告 1 / 21 2019 年第一季度报告 í 二、 11Í 四、 | --- | |----------------| | 目录 | | 重要提示 . | | 公司基本情况 . | | 重要事项 . | | 附录 . | 2 / 21 2019 年第一季度报告 单位：元 币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司董事长杨国占、总经理周晓冰、总会计师、财务负责人王立鑫及财务部部长李建军保证 季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | --- | |-------------------------------------------------|------------ ...

Financial Performance - The company's operating revenue for 2018 was RMB 9,213,775,284.29, representing a year-on-year increase of 19.52% compared to RMB 7,709,121,876.65 in 2017[22]. - The net profit attributable to shareholders of the listed company was RMB 22,490,775.36, showing a slight increase of 2.45% from RMB 21,952,245.00 in the previous year[22]. - The net cash flow from operating activities reached RMB 774,325,700.79, a significant increase of 169.56% compared to RMB 287,250,352.97 in 2017[22]. - As of the end of 2018, the total assets amounted to RMB 17,916,817,368.08, reflecting a growth of 4.46% from RMB 17,151,500,181.55 at the end of 2017[22]. - The total profit for the company reached 198 million yuan, indicating a positive trend in operational performance[57]. - Total profit reached CNY 198 million, a significant increase of 233.13% compared to the previous year[63]. - The company reported a net profit of ¥86,527,349.58, compared to a loss of ¥27,494,811.42 in the previous period, indicating a significant turnaround in profitability[86]. - The company reported a net profit of 203,162,115.52 RMB for 2018, with a retained earnings balance of 1,262,602,564.81 RMB at year-end[194]. Dividends and Shareholder Returns - The company plans to distribute cash dividends totaling RMB 48,924,141.87, which equates to RMB 0.30 per 10 shares based on the total share capital of 1,630,804,729 shares as of the end of 2018[6]. - The company reported a positive profit for the reporting period, with net income available for common shareholders being positive, but did not propose a cash profit distribution plan[196]. Research and Development - R&D expenses increased by 51.49% to CNY 71.88 million, reflecting the company's commitment to product development[64]. - The total R&D investment amounted to 332.70 million yuan, which is 3.61% of the operating revenue[80]. - The company has established a complete three-tier R&D system and is recognized as one of the first national enterprise technology centers[133]. - The company is actively pursuing the development of new drugs and technologies to mitigate the risks associated with high R&D costs and long cycles[141]. - The company has reported a total of 12,629.41 million RMB in cumulative R&D investment for the recombinant human albumin project, with ongoing clinical trials[142]. Market and Product Development - The company is focusing on developing high-value and high-growth projects in biopharmaceuticals and oncology drugs[31]. - The company is enhancing clinical academic research and evidence-based medicine to ensure the efficacy and safety of its products in response to the shift towards DRGs payment systems[99]. - The company is committed to improving its production supply capabilities and reducing costs while enhancing product quality and clinical efficacy[102]. - The company plans to enhance its product structure, shifting focus from raw materials to high-value formulations, and from anti-infection to specialized treatments[186]. - The company is expanding its sales network across most provinces and municipalities in China, utilizing a "distribution +招商 + academic promotion" sales model[156]. Risks and Challenges - There were no significant risks that materially affected the company's operations during the reporting period[7]. - The report includes a forward-looking statement risk declaration, indicating that future plans may involve uncertainties and do not constitute a substantive commitment to investors[6]. - The company is facing risks from policy changes such as the two-invoice system and national volume-based procurement, which may impact market share and pricing[162]. - The company faces risks from regulatory changes and rising costs in the pharmaceutical industry, necessitating structural adjustments and innovative marketing strategies[191]. Production and Sales - The company achieved a total revenue of 9.214 billion yuan in 2018, with a year-on-year growth of 28.26% in the pharmaceutical and chemical sector, which generated 8.437 billion yuan[57]. - The sales revenue from formulations reached CNY 6.316 billion, with 12 products exceeding CNY 100 million in revenue, including three products generating over CNY 700 million each[64]. - The company reported a significant increase in sales volume for key products, including 30,433 thousand units of injectable amoxicillin sodium and 27,328 thousand units of amoxicillin sodium and clavulanate potassium[163]. Strategic Focus - The company aims to enhance its drug research and development capabilities significantly, aspiring to become a leading domestic pharmaceutical R&D center[183]. - The strategic focus includes innovation-driven development, optimizing upgrades, and strengthening core competencies in the pharmaceutical sector[184]. - The company is committed to achieving a 100% pass rate in product market inspections and zero major quality incidents throughout the year[190]. Financial Stability - The company issued CNY 1 billion in short-term financing bonds to ensure financial stability[60]. - Cash and cash equivalents at the end of the period were 1.25 billion yuan, up 8.96% from the previous period[84]. - The company has made long-term equity investments totaling CNY 659 million, reflecting a 0.97% increase from the beginning of the year[173].